AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26764317 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and protein supplementation (300 kcal/d, 15 g protein/d)
Number of subjects: 24
Study 26764317 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and protein supplementation
Number of subjects: 24
Study 26764317 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 24
Study 24225233 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Cetuximab (400 mg/m2 loading dose one week prior to radiotherapy followed by weekly 250 mg/m2)
Number of subjects: 102
Study 24225233 — intervention group
Group type: COMPARATOR
Intervention: Concurrent daily Cisplatin (6 mg/m2) and radiotherapy (66 Gy in 24 fractions) without Cetuximab
Number of subjects: 102
Study 22730377 — intervention group
Group type: EXPERIMENTAL
Intervention: VT induced with four extrastimuli (ES)
Number of subjects: 432
Study 22730377 — intervention group
Group type: COMPARATOR
Intervention: VT induced with less than or equal to two ES
Number of subjects: 432
Study 22730377 — intervention group
Group type: COMPARATOR
Intervention: VT induced with three ES
Number of subjects: 432
Study 22730377 — intervention group
Group type: COMPARATOR
Intervention: VT induced with four ES
Number of subjects: 432
Study 22730377 — intervention group
Group type: COMPARATOR
Intervention: EP-negative patients
Number of subjects: 432
Study 20634747 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warm-up (WU)
Number of subjects: 27
Study 20634747 — intervention group
Group type: EXPERIMENTAL
Intervention: WU with dynamic stretching (ADS)
Number of subjects: 27
Study 20634747 — intervention group
Group type: COMPARATOR
Intervention: WU with static stretching (SPS)
Number of subjects: 27
Study 18375877 — intervention group
Group type: EXPERIMENTAL
Intervention: New multidisciplinary intervention (geriatric assessment and management by nurses at home)
Number of subjects: 151
Study 18375877 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 15789123 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group (14 patients)
Number of subjects: 28
Study 15789123 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term group (14 patients)
Number of subjects: 28
Study 15789123 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 patients)
Number of subjects: 28
Study 11773508 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL/d of green tea
Number of subjects: 35
Study 11773508 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL/d of black tea
Number of subjects: 35
Study 11773508 — intervention group
Group type: COMPARATOR
Intervention: Hot water containing caffeine
Number of subjects: 35
Study 11773508 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mL/d of black tea
Number of subjects: 35
Study 11773508 — intervention group
Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 35
Study 10192639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine hydrochloride (maximum dose administered for 30 weeks)
Number of subjects: 234
Study 7776299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 400
Study 7776299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 2104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 120 mg (40 mg t.d.s.)
Number of subjects: 11
Study 2104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 160 mg (loading dose of 80 mg)
Number of subjects: 11
Study 2104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 11
Study 2104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg
Number of subjects: 11
Study 392623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg prostaglandin E2
Number of subjects: 84
Study 392623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg prostaglandin E2
Number of subjects: 84
Study 392623 — intervention group
Group type: COMPARATOR
Intervention: inert material (control)
Number of subjects: 84
Study 392623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg prostaglandin E2, 0.4 mg prostaglandin E2, inert material (control)
Number of subjects: 84
Study 31142219 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transfer to endovascular center (endovascular treatment stroke center)
Number of subjects: 1754
Study 31142219 — intervention group
Group type: COMPARATOR
Intervention: Standard transfer to the closest local stroke center (local-SC)
Number of subjects: 1754
Study 31142219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1754
Study 28865351 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous testosterone (topical gel)
Number of subjects: 120
Study 28865351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26633251 — intervention group
Group type: EXPERIMENTAL
Intervention: $15 gift card
Number of subjects: 4427
Study 26633251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery for $250 gift card
Number of subjects: 4427
Study 26633251 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered incentive with choice of $15 gift card or lottery
Number of subjects: 4427
Study 26633251 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard reminder letter)
Number of subjects: 4427
Study 23928280 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae (ES) muscle activity during standing knee flexion
Number of subjects: 30
Study 23928280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle activity during standing knee flexion
Number of subjects: 30
Study 23928280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar motion during standing knee flexion
Number of subjects: 30
Study 21284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 83
Study 21284022 — intervention group
Group type: COMPARATOR
Intervention: Bladder Training (BT)
Number of subjects: 83
Study 19189940 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) training replacing 12 conventional training sessions over 4 weeks
Number of subjects: 23
Study 19189940 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 23
Study 16925952 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 230
Study 16925952 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 230
Study 12698087 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) continued with sirolimus (SRL) 2 mg/day (group I)
Number of subjects: 40
Study 12698087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 2 mg/day with early withdrawal of CsA (group II)
Number of subjects: 40
Study 10933120 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 7
Study 8637441 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein (VLDL) from hemodialysis patients
Number of subjects: 20
Study 1455006 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy
Number of subjects: 34
Study 1455006 — intervention group
Group type: COMPARATOR
Intervention: NO-EPO therapy (Control)
Number of subjects: 34
Study 3913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (32.5 mg)
Number of subjects: 31
Study 3913378 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg)
Number of subjects: 31
Study 31246052 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS‐C intervention
Number of subjects: 176
Study 31246052 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (control)
Number of subjects: 176
Study 30248943 — intervention group
Group type: EXPERIMENTAL
Intervention: Online 12-week walking intervention (STRIDE)
Number of subjects: 91
Study 30248943 — intervention group
Group type: COMPARATOR
Intervention: Control group (pedometer only)
Number of subjects: 91
Study 26792221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health supporters (LHSs) intervention with mobile phone messaging system
Number of subjects: 258
Study 26792221 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 258
Study 26792221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health supporters (LHSs) intervention
Number of subjects: 258
Study 23922377 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U vaccine
Number of subjects: 480
Study 23922377 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U vaccine
Number of subjects: 480
Study 23922377 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 U vaccine
Number of subjects: 480
Study 23922377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 22723853 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (150 to 450 mg/day)
Number of subjects: 846
Study 22723853 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 to 45 mg/day)
Number of subjects: 846
Study 20103455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular phloroglucinol (4 mL)
Number of subjects: 116
Study 20103455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, 4 mL)
Number of subjects: 116
Study 17762547 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ion channel blockers targeting atrial-specific ion channels or a combination of ion channels.
Number of subjects: 0
Study 17762547 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs inhibiting fibrosis, cellular hypertrophy, and improving cell-cell communication.
Number of subjects: 0
Study 17762547 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal pharmacological modulation targeting specific pathways.
Number of subjects: 0
Study 16153519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial electromechanical delay in MS group
Number of subjects: 25
Study 16153519 — intervention group
Group type: COMPARATOR
Intervention: Interatrial electromechanical delay in control group
Number of subjects: 25
Study 16153519 — intervention group
Group type: EXPERIMENTAL
Intervention: P-wave dispersion (PWD) in MS group
Number of subjects: 25
Study 16153519 — intervention group
Group type: COMPARATOR
Intervention: P-wave dispersion (PWD) in control group
Number of subjects: 25
Study 16153519 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between interatrial electromechanical delay and PWD
Number of subjects: 25
Study 12161530 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 20
Study 12161530 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional glucose uptake rates
Number of subjects: 20
Study 9612823 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative education (NORM) intervention
Number of subjects: 2370
Study 9612823 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure resistance training
Number of subjects: 2370
Study 9612823 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 2370
Study 8004580 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin treatment
Number of subjects: 277
Study 8004580 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin treatment)
Number of subjects: 277
Study 2509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 12
Study 2509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (300 micrograms)
Number of subjects: 12
Study 2509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms)
Number of subjects: 12
Study 2509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost (200 micrograms)
Number of subjects: 12
Study 2509214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 766905 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 40
Study 766905 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCG treatment)
Number of subjects: 40
Study 31393868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 10 mg/kg, one infusion
Number of subjects: 24
Study 31393868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 3 mg/kg every 8 weeks
Number of subjects: 24
Study 31393868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 10 mg/kg every 8 weeks
Number of subjects: 24
Study 31393868 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 24
Study 31393868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074
Number of subjects: 24
Study 28606587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal 25OHD levels at early pregnancy
Number of subjects: 0
Study 28606587 — intervention group
Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 0
Study 27087432 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent 24 h (n = 21)
Number of subjects: 39
Study 27087432 — intervention group
Group type: COMPARATOR
Intervention: Smoking as usual (n = 18)
Number of subjects: 39
Study 25103176 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen (400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily)
Number of subjects: 805
Study 25103176 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (tenofovir-emtricitabine 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily)
Number of subjects: 805
Study 25103176 — intervention group
Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen
Number of subjects: 805
Study 25103176 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 805
Study 22674570 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus epratuzumab
Number of subjects: 254
Study 22674570 — intervention group
Group type: COMPARATOR
Intervention: Standard R-CHOP
Number of subjects: 254
Study 19597081 — intervention group
Group type: EXPERIMENTAL
Intervention: creatine (n = 67)
Number of subjects: 413
Study 19597081 — intervention group
Group type: EXPERIMENTAL
Intervention: minocycline (n = 66)
Number of subjects: 413
Study 19597081 — intervention group
Group type: EXPERIMENTAL
Intervention: coenzyme Q10 (n = 71)
Number of subjects: 413
Study 19597081 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI‐1485 (n = 71)
Number of subjects: 413
Study 19597081 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 138)
Number of subjects: 413
Study 17615828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention PCG (children received a series of interventions including gift bags with a trainer cup, fluoride toothpaste (1450 ppm F), toothbrush, and parental advice on oral care)
Number of subjects: 0
Study 17615828 — intervention group
Group type: COMPARATOR
Intervention: Comparison PCG (no specific interventions mentioned)
Number of subjects: 0
Study 17615828 — intervention group
Group type: EXPERIMENTAL
Intervention: All children (participants and non-participants) in the active PCG
Number of subjects: 0
Study 17615828 — intervention group
Group type: COMPARATOR
Intervention: All children (participants and non-participants) in the comparison PCG
Number of subjects: 0
Study 14748760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 35
Study 14748760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily)
Number of subjects: 35
Study 14748760 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy subjects, no drug administration)
Number of subjects: 35
Study 11718678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry therapy
Number of subjects: 24
Study 11718678 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide treatment
Number of subjects: 24
Study 9752889 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium reduction (200 to 100 mmol/day)
Number of subjects: 12
Study 9752889 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict dietary sodium reduction (30 mmol/day)
Number of subjects: 12
Study 8001210 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-instructed ICU staff raters
Number of subjects: 16
Study 8001210 — intervention group
Group type: COMPARATOR
Intervention: Expert ratings
Number of subjects: 16
Study 2455740 — intervention group
Group type: COMPARATOR
Intervention: 5% human serum albumin (albumin)
Number of subjects: 12
Study 2455740 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (hetastarch)
Number of subjects: 12
Study 1986730 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine at 3 g/d
Number of subjects: 15
Study 1986730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 333252 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 75 mg daily for 14 days
Number of subjects: 0
Study 333252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30831041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib-induced proteinuria
Number of subjects: 259
Study 30831041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib-induced hypothyroidism
Number of subjects: 259
Study 30831041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib-induced cardiotoxicity grade 3-4
Number of subjects: 259
Study 28272252 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.35 μg/kg
Number of subjects: 120
Study 28272252 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 0.5 mg/kg
Number of subjects: 120
Study 28272252 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1 mg/kg
Number of subjects: 120
Study 28272252 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 120
Study 26259542 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0
Study 26259542 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 8 weeks
Number of subjects: 0
Study 26259542 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at birth vs 8 weeks
Number of subjects: 0
Study 25010879 — intervention group
Group type: EXPERIMENTAL
Intervention: Full veneer (FV) restorations
Number of subjects: 25
Study 25010879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap (OV) restorations
Number of subjects: 25
Study 25010879 — intervention group
Group type: COMPARATOR
Intervention: All-ceramic veneers (both designs)
Number of subjects: 25
Study 22463973 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pantoprazole, antacid, and antispasmodic
Number of subjects: 87
Study 22463973 — intervention group
Group type: COMPARATOR
Intervention: Placebo, antacid, and antispasmodic (conventional group)
Number of subjects: 87
Study 18365224 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 6 mL hylan G-F 20
Number of subjects: 100
Study 18365224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 4 mL hylan G-F 20
Number of subjects: 100
Study 18365224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 2 mL hylan G-F 20
Number of subjects: 100
Study 18365224 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 4 mL hylan G-F 20 (2 weeks apart)
Number of subjects: 100
Study 17229535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacter lactis supplemented preterm formula (2 x 10(7) cfu/g of dry milk)
Number of subjects: 41
Study 17229535 — intervention group
Group type: COMPARATOR
Intervention: Control group (same formula without supplementation)
Number of subjects: 41
Study 15152291 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 15152291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11842907 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium posts and composite cores
Number of subjects: 64
Study 11842907 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia posts and composite cores
Number of subjects: 64
Study 11842907 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia posts with heat-pressed ceramic cores
Number of subjects: 64
Study 11842907 — intervention group
Group type: COMPARATOR
Intervention: Cast posts and cores
Number of subjects: 64
Study 9728556 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple myeloma
Number of subjects: 27
Study 9728556 — intervention group
Group type: COMPARATOR
Intervention: Control patients with other cancers
Number of subjects: 27
Study 9728556 — intervention group
Group type: COMPARATOR
Intervention: Blood donors
Number of subjects: 27
Study 9728556 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with progressive multiple myeloma
Number of subjects: 27
Study 7752826 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ), 3.0‐3.4 mg/kg/day for 7 days
Number of subjects: 30
Study 7752826 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1, normals; group 4, asymptomatic children with MVP)
Number of subjects: 30
Study 7752826 — intervention group
Group type: COMPARATOR
Intervention: Patients with load-induced cardiac dysfunction (group 2)
Number of subjects: 30
Study 2544742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - 2,500 units 2 hours before surgery, then 5,000 units subcutaneously every morning for 9 days
Number of subjects: 90
Study 2544742 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin - 5,000 units every 8 hours
Number of subjects: 90
Study 2544742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 90
Study 2544742 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 90
Study 2544742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Conventional low-dose heparin
Number of subjects: 90
Study 31642731 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 15 mg
Number of subjects: 24
Study 31642731 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Number of subjects: 24
Study 31642731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31642731 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (repeated evening administration)
Number of subjects: 24
Study 31642731 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468
Number of subjects: 24
Study 30474592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model for outcome 1 (presence of at least one of the following symptoms at 9 months: persistent pain, functional difficulty, lack of confidence)
Number of subjects: 1266